Glaukos Submits PMA For iStent, Second-Generation MIGS Device For Treating Glaucoma

Glaukos Corp. announced on Dec. 27 it has submitted a pre-market approval application to US FDA for its second-generation minimally invasive glaucoma surgery (MIGS) iStent device used for treating glaucoma, the second-leading cause of blindness.